Assignee
HEMOGENYX PHARMACEUTICALS LLC
US·3 granted patents·3 pending applications·0 citations·filing 2017–2024
Top patents by PatentIndex Score
6 records- 0159US11945866B2Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodiesHEMOGENYX PHARMACEUTICALS LLC·Filed 2020·Granted Apr 2, 2024·0 cites·16 claims
- 0259US2025092112A1Chimeric bait receptors and uses thereofHEMOGENYX PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 0352US2024216432A1Anti-flt3 antibodies, cars, car t cells and methods of useHEMOGENYX PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 0451US2024368288A1Bispecific anti-flt3/cd3 antibodies and methods of useHEMOGENYX PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 0548US11021536B2Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodiesHEMOGENYX PHARMACEUTICALS LLC·Filed 2017·Granted Jun 1, 2021·0 cites·10 claims
- 0639US11104738B2Monoclonal antibodies to human FLT3/FLK2 receptor proteinHEMOGENYX PHARMACEUTICALS LLC·Filed 2019·Granted Aug 31, 2021·0 cites·25 claims
Join the waitlist — get patent alerts
Get an alert when HEMOGENYX PHARMACEUTICALS LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →